Acotec Scientific Holdings Limited (HKG:6669)

Hong Kong · Delayed Price · Currency is HKD

6.04

-0.27 (-4.28%)

Oct 2, 2026, 3:50 PM HKT

Market Cap	1.89B -53.5%
Revenue (ttm)	721.55M +5.4%
Net Income	-57.98M
EPS	-0.20
Shares Out	313.39M
PE Ratio	n/a
Forward PE	12.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	488,650
Open	5.90
Previous Close	6.31
Day's Range	5.90 - 6.28
52-Week Range	5.50 - 15.32
Beta	-0.04
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About HKG:6669

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries ... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2011

Employees 955

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 6669

Full Company Profile

Financial Performance

In 2025, HKG:6669's revenue was 644.63 million, an increase of 20.72% compared to the previous year's 533.99 million. Earnings were 119.18 million, an increase of 127.97%.

Financial numbers in CNY Financial Statements